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Abbreviations 
MM: mismatch 
SNP: single nucleotide polymorphism 
GWAS: genome-wide association study 
IRB: institutional review board 
CNI: calcineurin inhibitor 
PRA: panel reactive antibody 
TCMR: T-cell-mediated rejection 
AMR: antibody-mediated rejection 
MAF: minor allelic frequency 
LD: linkage disequilibrium 
OD: Odds ratio 
BCR: B-cell receptor 
 
Abstract 
Acute renal rejection is a major risk factor for chronic allograft dysfunction and long-term graft 
loss. We performed a genome-wide association study to detect loci associated with biopsy-
proven acute T cell-mediated rejection occurring in the first year after renal transplantation. In a 
discovery cohort of 4127 European renal allograft recipients transplanted in eight European 
centers, we used a DNA pooling approach to compare 275 cases and 503 controls, on Illumina 
2·5 M arrays. In an independent replication cohort of 2765 patients transplanted in two 
European countries, we identified 313 cases and 531 controls, in whom we genotyped 
individually the most significant SNPs from the discovery cohort. In the discovery cohort, we 
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found 5 candidate loci tagged by a number of contiguous SNPs (>5) that was never reached in 
iterative in silico permutations of our experimental data. In the replication cohort, two loci 
remained significantly associated with acute rejection in both univariate and multivariate 
analysis. One locus encompasses PTPRO, coding for a receptor-type tyrosine kinase essential 
for B cell receptor signalling. The other locus involves ciliary gene CCDC67, in line with the 
emerging concept of a shared building design between the immune synapse and the primary 
cilium.  
 
Introduction  
Acute rejection of renal allograft remains a major risk factor for the later development of 
chronic allograft dysfunction and long-term graft loss (1). Non adherence to therapy, HLA 
mismatches (MM), anti-HLA immunization, longer period of dialysis before transplantation, 
younger age, and prolonged cold ischemia time are recognized risk factors of acute renal 
rejection (2). Beside these classical immunological risk factors, genetic recipient background 
is likely to modulate the risk of acute rejection. Immune responses involved in the acute 
rejection process, mediated by T and B lymphocytes, are regulated through a complex, highly 
regulated network of molecular signals controlled by a large number of encoding genes, 
among which some could represent potential candidate that could be associated with an 
increased allo-reactivity.  
 
Numerous association studies of candidate genes have been reported in renal transplantation 
since year 2000, and dealt mainly with SNPs (Single Nucleotide Polymorphism) in genes 
encoding cytokines, chemokines, complement, toll-like receptors, and VEGF (3). These 
studies produced conflicting results, and were prone to false positive, spurious association 
findings because of inadequate sample size, population stratification, and lack of replication 
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in independent cohorts. To date, no genetic locus has clearly emerged as a risk or as a 
protection factor for acute rejection of solid organ allograft. 
 
In spite of the coming of age of whole genome sequencing, genome-wide association studies 
(GWAS) using arrays of SNPs, remain a powerful approach to identify novel genes or loci by 
analysing millions of genetic variants, with no a priori hypothesis on gene function, allowing 
for the discovery of previously unthought-of pathways. Studying genetic susceptibility of 
acute rejection is particularly complex. First, acute rejection is not a disease but a 
complication resulting from allo-reactivity that is modulated by factors from the recipient, the 
donor, and by immunosuppressive therapies. Second, apart from a case control retrospective 
study suggesting a trend for familial aggregation in recipients with acute rejection, there is no 
report from families where multiple members with renal failure received a kidney transplant 
(4). As transplantation is rarely familial, the existence of some major, mendelian or near-
mendelian, genetic factor predisposing to graft rejection would remain practically unnoticed 
as a hereditary phenotype. In the absence of evidence against such a major gene effect(s), we 
hypothesized that one or several genetic variants could confer a high relative risk of graft 
rejection, but no significant risk for disease outside the frame of transplantation, with a 
relative risk high enough for this gene(s) variant(s) to be amenable to a GWAS with suitable 
cohorts of transplanted patients. If this hypothesis is true, finding this gene(s) variant(s) 
would be an important milestone. 
 
Here, we gathered two large European cohorts of kidney transplant recipients, and report the 
first GWAS of biopsy-proven acute rejection occurring within the first year after transplant in 
low-immunological risk white patients receiving a first renal allograft. 
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Material and methods  
1. Patients 
1.1 Discovery Cohort 
We have collected DNA samples and clinical data from a total of 4127 patients transplanted 
in eight European renal transplant centers (Belgium: ULB-Hôpital Erasme- Brussels; France: 
CHU Tours, CHU Limoges, CHU Brest, CHU St-Etienne, CHRU Lille, CHU Poitiers and 
CHU Bordeaux) with written informed consent and institutional review board (IRB) approval 
(protocol number: P2007/106), and centralized them at the ULB-Hôpital Erasme. Amongst 
these, we selected white adults (≥18 years) having received a first renal transplantation with 
induction (anti-lymphocyte serum or monoclonal IL-2 receptor antagonist antibody), and 
calcineurin inhibitor (CNI) therapy at baseline. Exclusion criteria were: the presence of 
another solid organ transplant, the presence of anti-HLA antibodies (Luminex®) or a 
maximal panel reactive antibody (PRA) ≥5%, a follow-up period shorter than one year (if the 
cause was not related to graft loss due to rejection), and lack of DNA or clinical data 
available. Cases were defined as patients who developed at least one biopsy-proven acute T-
cell-mediated rejection (TCMR), defined by BANFF criteria, during the first year after 
transplantation (5). Patients with episodes of pure antibody-mediated rejection (AMR), 
untreated borderline or unexpected rejection (discovered in a protocol biopsy) were not 
eligible. Controls were defined as patients with neither acute nor chronic rejection - defined 
on the basis of a stable graft function (rise in serum creatinine between 6 and 12 months < 
20%) and absence of significant proteinuria (< 0·5g/day or negative urinary dipstick at 12 
months) – during the same period. Most participating centers did not perform systematic 
protocol biopsies, hence most controls were not biopsied. Amongst those, we selected for 
each case, two center-matched hypercontrols (graft recipients who did not present acute 
rejection in spite of an initially less favorable HLA match) with the highest possible number 
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of HLA mismatches in the order: 2xDR > 1xDR, 2xB > 1xB, 2xA > 1xB, 1xA mismatches. 
Patients older than 55 years receiving anti-lymphocyte serum at baseline (n=72) were not 
considered as hypercontrols, as they were felt to be at lower risk of developing acute 
rejection. A total of 328 cases and 588 hypercontrols were eligible in the database. After 
exclusion of patients with DNA of poor quality, 275 cases and 503 hypercontrols 
transplanted between 1986 and 2010 were genotyped (Fig 1).  
 
1.2 Replication cohort 
DNA samples and clinical data were collected with written informed consent and IRB 
approval (protocol number: P2007/106), from 2765 patients transplanted in two renal 
transplantation centers (Belgium: KUL Leuven, n=1068; Czech Republic: IKEM Prague, 
n=1697). Inclusion criteria for cases and controls were the same as for the discovery cohort, 
except for the requirement of induction therapy. We did not select hypercontrols for 
replication. This resulted in the selection of 333 cases and 593 controls in the database. A 
total of 313 cases and 531 controls transplanted between 1984 and 2011, with a genotyping 
rate > 90% were included in the association analyses (Fig 2).  
 
2. Genotyping 
2.1. Discovery cohort 
Genomic DNA was extracted using standard procedures. DNA quality was assessed for all 
samples by agarose gel electrophoresis, and samples with degraded DNA were excluded. 
DNA concentrations were estimated by fluorometry using Picogreen® (Invitrogen), as the 
average of three independent measurements with a coefficient of variation <0.10. Equimolar 
case and hypercontrol pools were generated by mixing 60ng of DNA from each of the 275 
cases and 503 hypercontrols, respectively. Pools were generated in triplicate, yielding three 
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case (CA, CB, CC) and three hypercontrol (HA, HB, HC) pools. 250ng DNA from each pool 
was hybridized on Human Omni 2.5-4 v1 DNA analysis BeadChip arrays® (Illumina). A 
(CA and HA) and B (CB and HB) pools were hybridized in duplicate, yielding five 
measurements for both cases and hypercontrols. Allelic frequencies in the pools were 
estimated from the B-allele frequencies computed with Genome Studio® (Illumina). We 
genotyped the 778 DNA samples individually for nine unlinked SNPs (rs11543947, 
rs2279804, rs17421009, rs2476601, rs3087243, rs3087456, rs7528684, rs4839469 and 
rs10804682) using Taqman SNP assays® as recommended by the manufacturer (Applied 
Biosystems) to evaluate the accuracy of the B-allele frequency estimates over a range of 
allelic frequencies.  
 
2.2 Replication cohort  
Genomic DNA was extracted and quantified using standard procedures. A total of 313 cases 
and 531 controls were genotyped (genotyping rate > 90%) individually for 18 SNPs selected 
for highest difference of B allelic frequency between cases and hypercontrols at loci 
identified as significant in the discovery cohort, using a Sequenom Mass Array iPLEX 
assay®. We genotyped at least three SNPs per locus. In addition, we genotyped SNP 
rs10846175 because the difference in B allele frequency was very high (0.21) in the 
discovery cohort, despite the fact that the variance of the allele frequency estimates was 
>0.001 for cases and hypercontrols. Three SNPs with a call rate < 90% were excluded from 
the analysis, leaving the other 15 SNPs eligible for the analyses. 
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3. Association analyses 
3.1 Power calculation 
Considering a rejection prevalence of 15% during the first year, the sample size of this 2-
stage GWAS (cases, n=588 and controls, n=1034) has a theoretical power of ≥ 80% to 
identify TCMR alleles with relative risks of 2·4, 1·63, 1·59 and 1·62 for minor allele 
frequencies (MAFs) of 0·05, 0·2, 0·3 and 0·5 respectively, under an additive genetic model 
(CATS calculator) (6,7).  
 
3.2 Significance of associated SNP clustering 
Categorical data were analyzed using Pearson's Chi square or Fisher’s exact tests as 
appropriate. t-test or Mann-Withey test were used to compare normally or non-normally 
continuous data. A bilateral p value smaller than 0.05 was used to reject the null hypothesis 
except for SNPs variables. First, we performed a univariate analysis, evaluating the 
association between the selected SNPs and acute rejection in the replication cohort using 
PLINK v1.07 (8). We estimated the statistical significance of the association from 
permutations performed within cohorts (respectively Leuven and Prague) to account for 
potential stratification. We applied a one-sided test by imposing that the difference in allelic 
frequency between cases and controls in the replication cohort would have the same sign as 
in the discovery control. Second, the association of SNPs with acute rejection after 
adjustment for other risk factors was assessed by multivariate logistic regression modelling. 
The model was constructed by progressively adding independent variables starting with those 
that had the strongest univariate association with the outcome of interest. In case of strong 
linkage desequilibrium (LD) between significant SNPs, only one SNP was included in the 
logistic regression to avoid co-linearity problems. The Wald test was used to test the null 
hypothesis of a log odds ratio (coefficient) equal to zero. The Hosmer and Lemeshow test 
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was used to check the goodness-of-fit of the model. A likelihood ratio test was used to assess 
whether adding a new variable to the model increased the overall log-likelihood. To test for a 
potential interaction between two risk factors we calculated stratum specific odds ratios and 
tested the null hypothesis of no difference between stratum-specific odds ratios by a chi-
squared test of homogeneity. 
 
Results 
1. A pool-based GWAS reveals 5 candidate risk loci for acute renal graft rejection 
From an initial cohort of 4127 patients having undergone a first renal transplantation, we 
selected 275 cases with acute TCMR within one year, and 503 hyper-controls without 
TCMR, despite being at higher risk of rejection using the specific criteria outlined above (Fig 
1). Baseline characteristics of the ensuing case-control cohort are reported in Table 1a. As 
expected from our study design, hypercontrols had a significantly higher number of HLA 
mismatches than cases, in particular HLA-DR mismatches (p<0·0001). The proportion of 
patients under steroids at 6 months was higher in cases, as a consequence of acute rejection 
occurrence (p<0·0001). Donors were significantly older in cases (p=0·035). The other 
characteristics were well balanced between the two groups.  
After very stringent evaluation of DNA quantity and quality, we generated equimolar DNA 
pools of the 275 cases and 503 hyper-controls in triplicates. The DNA pools were hybridized 
to arrays interrogating 2·5 million SNPs covering the entire genome, and allele frequencies 
were computed using Genome Studio® (Illumina). We genotyped the 778 DNA samples 
individually for nine unlinked SNPs showing a large range of allelic frequency using Taqman 
SNP assay, to evaluate the accuracy of the B-allele frequency estimates by Genome Studio 
software. The global coefficient of correlation (r2) exceeded 0.98, demonstrating the 
accuracy of our pooling method (Table S1). 
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 We first excluded 42526 SNPs for which the variance of the allele frequency estimates 
exeeded 0·001 (i.e. cases or hypercontrols). We then selected 1109 SNPs for which the 
average allele frequency between cases and hyper-controls differed by ≥0·10. We reasoned 
that true positive association would tend to involve multiple contiguous SNPs as a result of 
LD, and used a 50kb sliding window to scan the genome for clusters of positive SNPs. We 
identified five loci encompassing at least six such SNPs in a 50kb window. Iterative In silico 
permutations of our experimental data showed that more than 5 contiguous SNPs were never 
observed by chance alone in a 50kb window (after 100 in silico permutations, Table S2). The 
corresponding loci were assumed to be highly enriched in true risk loci for acute renal graft 
rejection. 
 
2. Two risk loci are replicated by individual SNP genotyping in an independent cohort. 
From two independent cohorts totaling 2765 patients transplanted in Leuven or Prague, we 
selected 333 cases with biopsy-proven acute TCMR and 593 matched controls. A total of 313 
cases (Belgian cohort, n=116; Czech cohort, n=197) and 531 controls (Belgian cohort, 
n=212; Czech cohort, n=319) with a genotyping rate > 90% were eligible for association 
analyses (Fig 2).  
 
Baseline characteristics of patients are reported in Table 1b. As observed in the discovery 
cohort, donors were older in patients with acute rejection (p=0·0006). Cases had significantly 
higher numbers of HLA mismatches, in particular HLA-DR mismatches (p<0·0001). The 
proportion of patients under tacrolimus was higher in cases (p=0·03). Other characteristics 
were well balanced between groups.  
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We individually genotyped all samples from the replication cohort using a Sequenom Mass 
ARRAY iPLEX assay interrogating 18 SNPs including at least three SNPs for each of the 5 
selected loci. SNPs with a call rate <90% (n=3) and individuals with a genotyping rate <90% 
were excluded (n=63). From fifteen SNPs with a genotype rate ≥90%, fourteen did not 
deviate significantly from Hardy-Weinberg equilibrium (p≥0·05), and were retained for 
further analysis. We first performed an association analysis under an additive model using 
Plink. We estimated the statistical significance of the observed association by permutations. 
Permutations were performed within cohorts to account for possible stratification that might 
differentiate the Belgian and Czech cohorts. Two SNPs replicating with a nominal p-value 
<0·05 were excluded because the difference in allelic frequency (between cases and controls) 
in the replication cohort had not the same sign as in the discovery cohort (chr5: rs2416500 
and chr5: rs6859254). Three SNPs in 2 from the 5 loci replicated with nominal p-value 
≤0·05: rs10765602 (p=0·007) on chr11:93048165, rs10846175 (p=0·007) and rs7976329 
(p=0·004) on chr12:15584624, and chr12:15602639, respectively. They remained 
significantly associated with TCMR after Sidak correction (Table 2). Genotype distribution 
of rs10765602 and rs7976329 in cases and controls is reported in Table S3. 
 
We then performed a genotype-based association test of the two corresponding regions 
jointly using a multivariate logistic regression analysis including donor age, type of CNI, 
administration of induction therapy or not, and number of HLA-DR mismatches as 
covariates. We only included one SNP per locus in these analyses because of the high LD 
between the SNP pair mapping to the same locus. Both rs10765602 (p=0·02) and rs7976329 
(p=0·01) remained significant independent risk factors of TCMR. Genotype-specific odds 
ratios (OR) suggested a recessive effect of the risk allele for the chr11 locus, and a dominant 
effect of the risk allele for the chr12 locus (Table 3). 
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SNP rs10765602 is located upstream CCDC67 (coiled-coil domain containing 67) alias 
DEUP1, a gene involved in centriole biogenesis in multiciliated cells (9). 
Variants rs10846175 and rs7976329 are in strong LD (r2= 0·93) and lie in the first intron of 
the PTPRO gene encoding protein tyrosine phosphatase receptor type O. PTPRO alias 
Glomerular Epithelial Protein-1 (GLEPP1) has two major isoforms. The PTPRO-FL (full-
length form) is a receptor-type protein tyrosine phosphatase expressed at the apical 
membrane of the podocyte foot processes. Rare, highly penetrant mutations cause a 
mendelian glomerulopathy characterized by a steroid-resistant childhood-onset nephrotic 
syndrome (10). PTPRO-T (truncated isoform) is encoded by an alternatively spliced form of 
PTPRO initially found to be expressed in naïve quiescent B cells and memory B cells (11). 
PTPRO regulates both the amplitude and timing of tyrosine phosphorylation-based B-cell 
receptor (BCR) signalling events and modulates protein tyrosine kinase-mediated cellular 
response. Both Lyn kinase and ZAP-70 tyrosine kinases are substrates of PTPRO-T (12,13). 
 
Discussion 
We here report what is to our knowledge the first GWAS of acute rejection in vast numbers of 
kidney transplant recipients. 
In a discovery cohort comparing TCMR and non-TCMR graft recipients, we identified five 
candidate loci tagged by a number (>5) of contiguous SNPs that was never observed by 
iterative in silico permutations of our experimental data, indicating strong enrichment for true 
positive signals. In an independent replication cohort, we confirmed the association with 2 
loci. These loci remained independent risk factors in a multivariate analysis integrating 
significant clinical risk factors. The OR associated with these SNPs was modest, except for 
rs10765602 where the GG genotype increased the risk of acute rejection by nearly two-fold.  
The number of renal graft recipient patients is limited and recruiting large cohorts is 
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notoriously difficult. We were hence impelled to include in our replication cohort patients 
who did not receive induction therapy. This choice may have caused loss of association 
power in our replication study. 
 
Variants rs10846175 and rs7976329 lie in the first intron of the PTPRO gene. PTPRO would 
have been an excellent a priori candidate gene for acute renal graft rejection as this gene 
might modulate alloreactivity through regulation of T-cell receptor (TCR) and BCR 
signalling and regulation of cytokine production. PTPRO plays several roles at the immune 
synapse. PTPRO substrate ZAP-70 is directly involved in TCR signalling and promotes TCR 
degradation by inducing receptor ubiquitination and targeting to lysosomes (13,14). PTPRO 
or ZAP-70 defects cause immune deficiency. ZAP-70-deficient patients have no functional T 
cells in their peripheral blood and suffer a severe combined immunodeficiency (15). Induced 
fulminant hepatitis in PTPRO-knockout (KO) mice showed that PTPRO deficiency led to 
inflammation attenuation and to a significant decrease in cytokine secretion by both T and 
natural killer cells leading to a marked impairment of NF-κB activation (16). The association 
between PTPRO SNPs and acute rejection was not tighter in the subgroup of patients with a 
glomerulopathy, excluding the potential association with acute rejection due to stratification 
only. 
 
Unexpectedly, we found an association of acute TCMR with ciliary gene CCDC67 alias 
DEUP1 (9).  Although the GWAS methodology does not demonstrate that the genes at, or 
near, the associated SNPs are the cause of the association, it allows for a reasonable 
hypothesis. Lines of evidence indicate tight similarities between the primary cilium and the 
immune synapse. Indeed, there are important architectural similarities, shared signalling 
platforms and common pathways for the two structures, supporting the idea that the immune 
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synapse is derived from the primary cilium (14,17). The CCDC67 locus association is 
unlikely to result from stratification of our cohorts for patients whose primary nephropathy 
was a known or even an unrecognized cilliopathy as there were no imbalances between 
groups regarding the proportion of glomerulopathies, tubulopathies or naturally, recognized 
primary cilium-related nephropathies (polycystic kidney disease, nephronophthisis, and 
Bardet-Biedl syndrome) (18). 
 
We have to acknowledge several limitations of our study. The DNA pooling approach is not 
as accurate as individual genotyping. However, genotyping using pooled DNA samples 
allows to measure allele frequencies at affordable costs and we applied a stringent 
methodology that minimizes errors (19-21). First, we pooled high quality DNAs with strict 
quantification in order to ensure that each individual DNA was represented in the same 
equimolar amount. Second, we obtained a good correlation between B allele frequency 
estimates by arrays and true B allele frequency calculated by Taqman individual genotyping 
(r2 > 0·98), similar to previous reports. Third, we minimized pipetting variability by 
constructing triplicates and batch (array) variability by constructing duplicates. Fourth, in 
order to reduce the chance of false positive results, we ranked SNPs based on B allele 
frequency differences and we excluded SNPs with a variance above 0.001. Finally, we 
considered for replication, only loci with 6 or 7 contiguous SNPs, a significant number that 
was never observed by chance alone after 100 in silico permutations of our experimental 
data, minimizing the risks of false positive results.  
 
We studied TCMR instead of a more fixed phenotype such as long-term graft failure. Indeed, 
TCMR, which is associated with poorer long-term graft outcome, is closely related to 
immune causes, whereas graft failure is related to immune as well as non-immune processes. 
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Likewise, we did not include pure antibody-mediated acute rejection, which is associated 
with heterogeneous immunological risk factors and involves different pathways, likely to be 
associated with different genetic risk factors (22). The timing (TCMR within the first year) is 
well justified by the fact that most TCMRs occur during the first 3 months, while late acute 
rejection episodes (after one year) are often the consequences of non-adherence. 
 
Some heterogeneity in immunosuppression must be acknowledged, due to the differences in 
immunosuppression protocols in the centers. First, regarding tacrolimus, the proportion of 
patients is higher in the replication cohort. This difference might be related to a lower use of 
induction therapy (100% in the discovery cohort versus 27% in the replication cohort). The 
use of tacrolimus (instead of cyclosporine) is likely due to an effort to balance the absence of 
induction, in order to minimize the risk of acute rejection. Second, regarding steroids, part of 
the difference is also likely to be due to centers’ practices, with more centers in the discovery 
cohorts discontinuing steroids at 6 months if no rejection had occurred since transplantation. 
Along the same line, we must also acknowledge the slight differences with regard to cold 
ischemia time and dialysis duration. The higher number of HLA MM in controls (discovery 
cohort) is intentional and related to the selection of hypercontrols. Hypercontrols are control 
individuals from the lower extremity of the relevant trait distribution and a study design using 
hypercontrols is a powerful approach in GWAS focusing on one disease (23). Among 
controls, we have selected recipients with highest number of HLA MM, at theoretically 
higher risk of acute rejection, in order to maximize the chance to find at-risk variants. 
Conversely, in the replication cohort, there was a higher number of HLA MM in cases, 
because we did not select for hypercontrols.  
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These differences are unlikely to bias our results. The fact that rs10765602 and rs7976329 
were significant in both cohorts and remained independent risk factors in the multivariate 
analysis (Table 3) strongly supports a causal risk independently of other factors.  
 
Studies in renal transplantation are notoriously limited in the number of available patients 
with sufficient homogeneity, as opposed to frequent complex traits like diabetes or 
hypertension. The present GWAS was therefore not powered to detect frequent alleles 
conferring a low risk of acute rejection, or low frequency or rare alleles (MAF<0·005). In 
addition, true associations might have been missed by the exclusion of SNPs, using the 
stringent quality filters set in our discovery cohort. 
 
In conclusion, the present GWAS addressed the important scientific issue of the genomic 
basis for immune rejection of the allograft and provides strong evidence for PTPRO, a 
lymphocyte receptor-type tyrosine kinase gene and CCDC67, a ciliary gene, being involved 
in the acute rejection of renal transplants. These novel genes may help understand the 
molecular pathways involved in acute rejection, which may in turn lead to the development 
of novel anti-rejection approaches. Furthermore, novel genetic biomarkers that reflect 
individual susceptibilities to graft rejection could provide the rationale for customized 
immunosuppression by allowing the pre-graft identification of low- and high -risk patients. 
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Figure Legends 
Figure1: Discovery cohort: Flowchart of patients included 
* Death, lost of follow-up, graft loss for another reason than rejection 
** Not biopsy-proven, protocol biopsy, borderline not treated, or pure humoral rejection 
Tx : transplantation, PRA : panel reactive antibody, CNI : calcineurin inhibitor 
Figure 2: Replication cohort: Flowchart of patients included 
 * Death, lost of follow-up, graft loss for another reason than rejection 
** Not biopsy-proven, protocol biopsy, borderline not treated, or pure humoral rejection 
*** Including 951 patients without induction 
Tx : transplantation, PRA : panel reactive antibody, CNI : calcineurin inhibitor 
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Table 1a: Discovery cohort: Baseline characteristics of patients (n=778) 
 
Characteristics Cases  (N=275) 
Hypercontrols  
(N=503) 
P 
Recipient age: mean±SD (y) 48·3 ±14·1 48·6 ± 13·4 0·77 
Recipient sex (male): n (%) 179 (65·1) 331 (65·8) 0·84 
Type of Donor (cadaveric): n (%) 263 (95·6) 481 (95·8) 0·91 
Donor age: mean±SD (y) 47·2 ± 15·9 44·7 ± 15·9 0·035 
Donor sex (male): n (%) 148 (54) 294 (60) 0·11 
Cold ischemia time: mean±SD (h) 19·4 ± 7·7 18·3 ± 7·9 0·07 
Dialysis duration: median (P25-P75)  
(m) 
18 (8·9-36) 18 (9·5-30·8) 0·97 
Primary Nephropathy: n 
Glomerulopathy 
Nephroangiosclerosis/Hypertension 
Polycystic kidney disease 
Diabetic 
Chronic interstitial nephropathy 
Uncertain 
Other 
Congenital/Hereditary 
 
 
80 
25 
52 
13 
30 
33 
18 
22 
 
 
143 
24 
107 
22 
54 
73 
35 
44 
0·45 
Steroids at 6 months (yes): n (%) 249 (93·3) 328 (65·7) <0·0001 
Tacrolimus/Cyclosporin: n 92/183 204/299 0·05 
Induction (Thymoglobulin/IL2R 
antagonist): n 
75/200 154/349 0·33 
HLA-A MM (0/1/2): n 38/149/86 47/270/186 0·09 
HLA-B MM (0/1/2): n 25/129/119 21/215/267 0·003 
HLA-DR MM (0/1/2): n 30/154/88 10/272/221 0·0003 
HLA B+DR MM: mean±SD  2·56 ± 0·93 2·91 ± 0·71 <0·0001 
HLA A+B+DR MM: mean±SD  3·73 ± 1·24 4·20 ± 0·95 <0·0001 
 
Legend of Table 1a: 
SD: standard deviation, MM: mismatch 
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Table 1b: Replication cohort: Baseline characteristics of patients (n=844) 
 
Characteristics Cases  (N=313) 
Controls  
(N=531) P 
Recipient age: mean±SD (y) 51·3±13·2 52±12·9 0·44 
Recipient sex (male): n (%) 205 (65·5) 350 (65·9) 0·90 
Type of Donor (cadaveric): n (%) 268 (85·6) 457 (86·1) 0·86 
Donor age: mean±SD (y) 50±14·3 46·4±14·8 0·0006 
Donor sex (male): n (%) 166 (53·2) 299 (56·5) 0·35 
Cold ischemia time: mean±SD (h) 14·3±6·8 14·4±6·8 0·90 
Dialysis duration: median (P25-P75)  
(m) 24 (12-41·8) 23 (11·5-38) 0·24 
Primary Nephropathy: n 
Glomerulopathy 
Nephroangiosclerosis/Hypertension 
Polycystic kidney disease 
Diabetic 
Chronic interstitial nephropathy 
Congenital/Hereditary  
Uncertain 
Other 
 
95 
25 
49 
28 
30 
48 
22 
16 
 
177 
29 
107 
34 
50 
84 
27 
23 
0·34 
Steroids at 6m (yes): n (%) 276 (92·3) 488 (92·1) 0·91 
Tacrolimus/Cyclosporin: n 251/62 390/141 0·03 
Induction therapy: n (%) 95 (30·4) 130 (24·5) 0·06 
HLA-A MM (0/1/2): n 37/175/98 94/285/146 0·06 
HLA-B MM (0/1/2): n 38/162/110 67/286/172 0·72 
HLA-DR MM (0/1/2): n 83/166/61 203/273/48 <0·0001
HLA B+DR MM: mean±SD  2·2±1·0 1·9±0·9 0·0002 
HLA A+B+DR MM: mean±SD  3·4±1·3 3·00±1·3 0·0001 
 
Legend of Table 1b: 
SD: standard deviation, MM: mismatch 
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Table 2: Replicated SNPs: corresponding MAF in the discovery cohort and univariate analysis in the replication cohort 
 
SNP Discovery cohort Replication cohort 
Chr SNP Position Minor 
allele 
MAF 
in 
cases 
MAF 
in 
CTRLS
Delta 
MAF 
MAF 
in 
cases 
MAF 
in 
CTRLS
Delta 
MAF 
OR 95% CI P* P** 
5 rs182190 70840233 A 0·41 0·56 -0·15 0·43 0·44 -0·02 0·94 0·77-1·14 0·333 0·868 
5 rs277978 70926559 G 0·45 0·54 -0·09 0·42 0·44 -0·02 0·92 0·76-1·13 0·153 0·564 
5 rs2416500 117376303 G 0·36 0·2 0·16 0·19 0·25 -0·05 0·73 0·57-0·93 0·007 0·033 
5 rs10079827 117424611 C 0·41 0·27 0·14 0·23 0·26 -0·02 0·88 0·69-1·11 0·163 0·589 
5 rs6859254 117438003 G 0·34 0·22 0·12 0·19 0·24 -0·04 0·77 0·60-0·98 0·017 0·081 
11 rs10765602 93048165 G 0·36 0·26 0·1 0·35 0·29 0·06 1·32 1·07-1·63 0·007 0·036 
11 rs200848508 93082760 G 0·49 0·6 -0·11 0·47 0·49 -0·03 0·90 0·74-1·10 0·144 0·541 
11 rs3020071 93105965 G 0·42 0·52 -0·1 0·45 0·47 -0·02 0·91 0·75-1·12 0·262 0·781 
12 rs1461039 15577935 C 0·44 0·55 -0·11 0·43 0·47 -0·04 0·90 0·74-1·10 0·073 0·316 
12 rs10846175 15584624 G 0·51 0·3 0·21 0·36 0·30 0·06 0·85 0·69-1·03 0·007 0·037 
12 rs7976329 15602639 C 0·49 0·31 0·18 0·37 0·30 0·06 1·30 1·06-1·61 0·004 0·020 
14 rs1952836 28576698 A 0·28 0·16 0·12 0·27 0·28 0·00 1·33 1·08-1·63 0·500 0·969 
14 rs1191395 28693834 G 0·63 0·47 0·16 0·46 0·47 -0·02 0·99 0·80-1·25 0·184 0·639 
14 rs942630 28702660 A 0·56 0·43 0·13 0·46 0·47 -0·02 0·93 0·77-1·15 0·333 0·868 
 
Legend for Table 2: 
* P-value after permutation (to control for potential stratification for the 2 sub-cohorts Leuven and Prague) 
** P-value after Sidak correction (for 5 loci) 
Chr : chromosome• MAF : minor allelic frequency• CTRLS : controls, OR:odds ratio, CI: confidence interval 
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Table 3: Multivariate logistic regression analysis (n=829 /cases=309) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable OR 95% CI p
Donnor age  
(increase per year) 1·02 1·01-1·03 0·002 
Calcineurin inhibitor : 
Tacrolimus 
Cyclosporin 
 
1 
0·70 0·5-1·00 0·05 
Induction : 
No induction 
Induction 
 
1 
1·37 
 
 
0·99-1·91 
 
 
0·06 
HLA-DR MM (n) 
0 
1 
2 
 
1 
1·38 
2·88 
 
 
0·99-1·92 
1·80-4·60 
 
 
 
0·0001 
rs10765602 (genotype) 
TT 
GT 
GG 
 
1 
1·07 
1·98 
 
 
0·79-1·47 
1·21-3·25 
 
 
 
0·02 
rs7976329 (genotype) 
TT 
CT 
CC 
 
1 
1·59 
1·61 
 
 
1·16-2·17 
0·96-2·70 
 
 
 
0·01 
Legend of Table 3:  
OR : odd ratio, CI : confidence interval, MM : mismatch 
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